Navigation Links
Novexel to be Acquired by AstraZeneca
Date:12/23/2009

d $17bn in 2008.[1]

Novexel currently has two novel antibacterials in Phase II clinical development. These are the injectable beta-lactamase inhibitor, NXL104 and the oral streptogramin antibiotic, NXL103. NXL104 is being developed in combination with the cephalosporin antibiotic ceftazidime (CAZ-104) and is currently in two Phase II clinical trials in patients with complicated intra-abdominal infections (cIAIs) and patients with complicated urinary tract infections (cUTIs). Under an agreement concluded in January 2008, Novexel granted Forest Laboratories ( FRX) the rights to develop NXL104 in combination with ceftaroline (CEF-104) solely in North America.

NXL103 is currently in a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). NXL103 has previously delivered positive Phase II results in a trial evaluating it in the treatment of community acquired pneumonia (CAP).

In addition, Novexel has two further programmes in preclinical development, NXL105, a novel anti-Pseudomonal antibiotic and NXL201, a novel echinocandin antifungal agent.

Novexel was created in December 2004 as an independent spin-out of the sanofi-aventis (Euronext Paris: SAN, SNY) anti-infectives unit. Novexel has a team of 54 employees with significant experience in anti-infective research and development, who are located in Paris, France and Philadelphia, USA.

Novexel's investors are Sofinnova, Atlas Venture, Novo A/S, Abingworth, Edmond de Rothschild Investment Partners, Goldman Sachs, NeoMed and Daiwa SMBC Capital Co., Ltd.

    [1] Source: IMS Health, MIDAS, 2006-2008

    For further information please contact:

    Novexel
    Gordon Waldron, CFO
    gordon.waldron@novexel.com

    Citigate Dewe Rogerson
    David Dible/Amber Bielecka/Nina Enegren
    Tel.: +44-(0)207-638-95-71
    '/>"/>
SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
2. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
3. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
4. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
5. Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
6. Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
9. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
10. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
11. Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- Market Research Report on Global ... a professional and in-depth market survey on ... The report firstly reviews the basic information of ... manufacturing technology. The report then explores global and ... their product specification, capacity, Production value, and market ...
(Date:8/29/2014)... 29, 2014 Pomerantz LLP has filed a ... "Company") (NASDAQ: EDAP ) and certain of ... District Court, Southern District of New York ... of a class consisting of all persons or entities ... July 30, 2014, inclusive (the "Class Period"). This class action ...
(Date:8/29/2014)... Aug. 29, 2014  BC Technical, the nation,s leading ... Medical Imaging, a leader in sales, service and installation ... allows BC Technical to continue to expand their resources ... and CT modalities. "We are committed ... Mark Alvarez , president and CEO of BC Technical. ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3BC Technical Acquires Polaris Medical Imaging 2
... 2012   CareFusion today announced an agreement to ... that helps hospital pharmacies better manage inventory, reduce pharmaceutical ... not disclosed. The acquisition will advance CareFusion,s ... to manage medication throughout their facilities – from ...
... March 6, 2012 Life Length, the ... Drs Sandy Chang and Kathleen Collins have joined its ... CEO, Life Length, noted, "We are delighted to welcome ... SAB. They will help advance our global leadership.  Dr ...
Cached Medicine Technology:CareFusion To Acquire Pharmacy Automation Technology Leader 2CareFusion To Acquire Pharmacy Automation Technology Leader 3CareFusion To Acquire Pharmacy Automation Technology Leader 4Drs Sandy Chang and Kathleen Collins Join LIFE LENGTH®'s Scientific Advisory Board 2
(Date:8/30/2014)... Market Research Report on Global and ... and in-depth market survey on Global and Chinese ... basic information of Cell Disruptor including its classification, ... global and China’s top manufacturers of Cell Disruptor ... market share etc. The report further analyzes quantitatively ...
(Date:8/30/2014)... Continuing to meet the skin health needs ... addition of a new doctor and office in Grand ... skin care in Grand Rapids since 1980 is merging ... doctor, my passion is making sure my patients receive ... I’m better able to focus on my patients and ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 "My wife ... of a car accident," said one of two inventors ... strain in her shoulder and neck area. She tried ... reduced pain and pressure, assisting in comfort and providing ... patent-pending PILLOW CRADLE to support the head, neck and ...
(Date:8/30/2014)... Serving contented clients since inception, #1 web design ... is now offering discount for Labor Day on all ... putting forward the best of web development technology before ... of professionals and web developers and designers has expertise ... critical issues of web development and can develop websites ...
(Date:8/30/2014)... Saturday 30 August 2014: Transvenous lead extraction (TLE) ... according to data from the European Lead Extraction ConTRolled ... ESC Congress 2014 by Dr Maria Grazia Bongiorni, chair ... "The number of cardiac implantable electronic devices (CIED) implant ... technology the number of complications has increased and leads ...
Breaking Medicine News(10 mins):Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4Health News:Expanding Care at the Forefront of Dermatology 2Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3
... Biotech Group (USA), Inc.,(the "Company" or "Tiens", NYSE AlternextUS: ... for the twelve months ended,December 31, 2008. , ... 31, 2008, revenue was $77.2 million,an increase of 40.7% ... 31, 2007. , Net income ...
... John Lawson Cullison, Jr., an artist known for his work ... lost his ability to paint due to the effects of ... in cartilage tissue and symptoms include: pain, tenderness in the ... Pain management and joint replacement surgery are the typical ...
... for 21st century patient safety, says Dr. FriedbergCORONA ... Society of Anesthesiologists, (ASA) April ,Anesthesiology, reports of ... over medication (translation: ,TOO MUCH, anesthesia)," says Dr. ... brain activity monitors (BAMs), FDA approved and available ...
... new study in The Journal of Nursing Administration ... patients when continuous vigilance monitoring is used on medical-surgical ... Patrick Sullivan, President and CEO of Hoana Medical, Inc. ... RNs about potential patient deterioration so they can respond ...
... 31 , - ... and Smartphone,Applications , Elsevier, ... the winners in the Elsevier Article 2.0 Contest ... creative and useful solutions for rendering journal articles ...
... across North Carolina , ... Englewood, CO (Vocus) March ... science careers and information, unveiled the seventh edition of the ... ,This regional campaign is a promotional effort highlighting biotechnological, pharmaceutical and ...
Cached Medicine News:Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 2Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 3Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 4Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 5Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 6Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 7Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 8Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 9Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 10Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 11Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 12Health News:Korean Stem Cells Allow Artist to Paint Again 2Health News:American Society of Anesthesiologists - 2,211 Patient Deaths From OVER Medication 2Health News:Continuous Vigilance Monitoring Technology Benefits Nurses & Patients 2Health News:Three Prize Winners Awarded in Elsevier's Article 2.0 Contest 2Health News:Three Prize Winners Awarded in Elsevier's Article 2.0 Contest 3Health News:BioSpace Launches the 2009 Bio NC™ Hotbed Campaign 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: